Status:
UNKNOWN
PD-1 Inhibitor Concurrent With Chemotherapy as Neoadjuvant Therapy for TNBC
Lead Sponsor:
First Affiliated Hospital, Sun Yat-Sen University
Conditions:
Triple Negative Breast Cancer
Eligibility:
FEMALE
18-60 years
Phase:
PHASE2
Brief Summary
The purpose of the study is to address the following hypotheses: the PD-1 inhibitor Sintilimab 200mg for intravenous (IV) administration will be given together with three-week epirubincin, cyclophosph...
Eligibility Criteria
Inclusion
- Newly diagnosed histologically confirmed stage I-III, ER, PR and HER2 negative invasive breast cancer as defined by the ASCO CAP guidelines for whom systemic chemotherapy would be indicated based on physician judgment following standard NCCN practice guidelines.
Exclusion
- Patients for whom anthracycline, nab-paclitaxel or antibody therapies are contraindicated.
Key Trial Info
Start Date :
March 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2024
Estimated Enrollment :
49 Patients enrolled
Trial Details
Trial ID
NCT04809779
Start Date
March 1 2021
End Date
March 1 2024
Last Update
March 22 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The First Affiliated Hospital of Sun Yat-sen University
Guangzhou, China